Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment

被引：0
|
作者：
Ivans, Andrea [1 ]
Stringfellow, Joseph [2 ]
Coric, Vladimir [1 ]
Croop, Robert [1 ]
机构：
[1] Biohaven Pharmaceut Inc, New Haven, CT USA
[2] Navitas Life Sci, Princeton, NJ USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2126
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group Study
    Bhardwaj, Rajinder
    Ivans, Andrea
    Stringfellow, Joseph
    Morris, Beth
    Coric, Vladimir
    Croop, Robert
    Bertz, Richard
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (08): : 790 - 800
  • [2] Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment
    Croop, Robert
    Stringfellow, Joseph
    Ivans, Andrea
    Coric, Vladimir
    CEPHALALGIA, 2019, 39 : 200 - 200
  • [3] Rimegepant 75 mg in Subjects with Hepatic Impairment: Results of a Phase 1, Open-label, Single-dose, Parallel-group Study
    Croop, R.
    Stringfellow, J.
    Ivans, A.
    Coric, V
    HEADACHE, 2019, 59 : 178 - 178
  • [4] Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study
    Chen, Xinhui
    Cui, Xiaoming
    Pognan, Nathalie
    Quinlan, Michelle
    Kapoor, Shruti
    Rahmanzadeh, Gholamreza
    Giovannini, Monica
    Marbury, Thomas C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 91 - 102
  • [5] Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Croop, Robert
    Stringfellow, Joseph
    Ivans, Andrea
    Coric, Vladimir
    CEPHALALGIA, 2019, 39 : 30 - 30
  • [6] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Bhardwaj, Rajinder
    Morris, Beth
    Bertz, Richard
    Croop, Robert
    Liu, Jing
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (01): : 37 - 44
  • [7] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Croop, R.
    Stringfellow, J.
    Ivans, A.
    Coric, V
    HEADACHE, 2019, 59 : 177 - 178
  • [8] Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Ivans, Andrea
    Stringfellow, Joseph
    Coric, Vlad
    Croop, Robert
    NEUROLOGY, 2020, 94 (15)
  • [9] Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study
    Chattopadhyay, Niladri
    Riecke, Kai
    Ligges, Sandra
    Zimmermann, Torsten
    Halabi, Atef
    Schultze-Mosgau, Marcus-Hillert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 2011 - 2021
  • [10] Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
    Peveling-Oberhag, Jan
    Zeuzem, Stefan
    Yong, Wei Peng
    Kunz, Tiffany
    Paquet, Thierry
    Bouillaud, Emmanuel
    Urva, Shweta
    Anak, Oezlem
    Sellami, Dalila
    Kobalava, Zhanna
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 215 - 225
12345